NIH R01 · 2025
Mechanistic study and therapeutic application of AIBP in AMD
PROJECT SUMMARY Choroidal neovascularization (CNV), the wet type of age-related macular degeneration (AMD), is a major cause of blindness in the elderly. Current anti-vascular endothelial growth factor (VEGF) therapy has a number of serious limitations including: 1) many patients respond poorly or not at all to mono anti-VEGF treatments (non-responders); 2) the long-term outcomes are suboptimal even for responders and can lead to anti-VEGF resistance; 3) repetitive intravitreal injections adversely affect quality of life and increase the risk of local complications. Therefore, alternative or combination therapies to improve CNV treatment efficacy represent a major unmet clinical need.…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.